Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Current sort

How Leukemia studies are organized in the registry

“Leukemia” is an umbrella term; in practice most records name the specific subtype, and this directory has dedicated pages for the major ones — acute myeloid (AML), chronic lymphocytic (CLL), and acute lymphoblastic (ALL) leukemia. Use this page when scanning across subtypes, and the subtype pages when you know which disease you mean.

Terms that often appear in related listings

AML CLL ALL CML relapsed refractory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 13–24 of 12 matching trials for Leukemia.

Live ClinicalTrials.gov results.

Active filters: "ALL" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Interventions: AMX-883, Posaconazole; Drug
Lead sponsor: Amphista Therapeutics Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
Interventions: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500; Drug · Biological · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 5
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 141
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 120 more

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Interventions: Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab; Drug · Other · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 291
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more

Conditions: Prostate Cancer, Leukemia, Breast Cancer, Melanoma, Colorectal Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 64,277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Interventions: bezuclastinib; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more

Conditions: Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Ultrasound Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2029
U.S. locations: 5
States / cities: Bethesda, Maryland • Detroit, Michigan • Rochester, Minnesota + 2 more

Conditions: Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Interventions: olverembatinib, Bosutinib; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 50
States / cities: Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 44 more

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
Interventions: Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, G-csf, Mesna, CliniMACS, ATG (rabbit), Blinatumomab, TCRα/β+, CD19+, CD45RA-depleted DLI; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: B-All, Acute Lymphoblastic Leukemia
Interventions: TSLPR-CART, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions: RVU120(SEL120); Drug
Lead sponsor: Ryvu Therapeutics SA; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more

About this Leukemia clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Leukemia clinical trials

How Leukemia studies are organized in the registry

Filter and sort this condition

Live official records

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Natural History Study of Early Life Exposures in Agriculture (ELEA)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Study of Olverembatinib (HQP1351) in Patients With CML-CP

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

About this Leukemia clinical trials directory page